• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.170 -0.030 (-2.50%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,685
Open 1.200
Bid (Size) 1.140 (100)
Ask (Size) 1.250 (500)
Prev. Close 1.200
Today's Range 1.150 - 1.220
52wk Range 0.8885 - 2.091
Shares Outstanding 34,380,971
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Telomir-Zn Improvements in Visual Function and Retinal Structure in AMD Model
September 17, 2026
Via Investor Brand Network
News headline image
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
September 17, 2026
Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic Biology 
From Telomir Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-12.7%
-12.7%
1 Month
+4.5%
+4.5%
3 Month
-10.0%
-10.0%
6 Month
-11.4%
-11.4%
1 Year
-15.8%
-15.8%

More News

Read More
NetworkNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Telomir-Zn Growth Inhibition Across Human and Canine Osteosarcoma Models
September 14, 2026
Via Investor Brand Network
News headline image
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
September 14, 2026
From Telomir Pharmaceuticals, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Telomir-Zn Data Supporting Phase 1/2 TNBC Program
August 10, 2026
Via Investor Brand Network
News headline image
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
August 10, 2026
From Telomir Pharmaceuticals, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Publishes Preclinical Data Showing Improved Insulin Sensitivity in Type 2 Diabetes Model
June 15, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
June 15, 2026
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson’s Disease
May 20, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
May 20, 2026
Via ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026
Via ACCESS Newswire
MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Closes TELI Acquisition, Secures Global Rights to Telomir-1
April 24, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
April 24, 2026
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Submits IND for TNBC Candidate Telomir-1
March 31, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
March 31, 2026
Via ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models
February 17, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
February 17, 2026
Via ACCESS Newswire
BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn
February 05, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
February 05, 2026
Via ACCESS Newswire
MissionIRNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Positive Telomir-1 Results In TNBC Zebrafish Xenograft Study
January 05, 2026
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
January 05, 2026
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
December 18, 2025
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
December 18, 2025
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
November 25, 2025
Via ACCESS Newswire

Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?
Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market
What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?
The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 1.170
When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 10/01/26 04:00 PM ET
What is the market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock is 40.23M
How many shares of Telomir Pharmaceuticals, Inc. - Common Stock are outstanding?
Telomir Pharmaceuticals, Inc. - Common Stock has 40M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap